LGD-4033 and Ondansetron Interaction

Avoid
Mechanism-based 64% confidence

LGD-4033 and Ondansetron have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Ondansetron

5-HT3 Antagonist | Anti-Nausea On Cycle

Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem.

Half-life: ~4 hours Typical dose: 4-8 mg as needed other
cyp3a4glp1 receptorserotonin receptor cardiotoxichepatotoxic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (LGD-4033, Ondansetron). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take LGD-4033 with Ondansetron?

Combining LGD-4033 with Ondansetron is not recommended. Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Ondansetron safe together?

This combination carries significant risk. Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Ondansetron?

Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Ondansetron?

LGD-4033 has a half-life of ~24-36 hours and Ondansetron has a half-life of ~4 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Ondansetron

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.